Sarepta Therapeutics Sees FY25 Net Product Revenue $2.9B-$3.1B Vs $3.24B Estimate
Portfolio Pulse from Benzinga Newsdesk
Sarepta Therapeutics has projected its FY25 net product revenue to be between $2.9 billion and $3.1 billion, which is below the market estimate of $3.24 billion.
August 07, 2024 | 8:37 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sarepta Therapeutics has projected its FY25 net product revenue to be between $2.9 billion and $3.1 billion, which is below the market estimate of $3.24 billion.
The revenue projection for FY25 is below market expectations, which could lead to a negative short-term impact on the stock price as investors may adjust their valuations based on the lower-than-expected revenue guidance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100